FinTechFunding

PharmAust: Begins recruiting dogs for canine cancer trial

  • PharmAust (PAA) has officially started recruiting patients for a second-phase clinical trial testing one of its key drugs against cancer in dogs
  • The phase IIb trial will test PharmAust’s monepantel (MPL) treatment against naive B-cell lymphoma in dogs
  • This is one of the most common types of cancer in dogs, accounting for around 20 per cent of all canine cancers
  • PharmAust has started treating eligible dogs with MPL under the trial and also started giving six dogs not eligible for the trial compassionate treatment
  • The company says the overall market for veterinary medicinal products is more than $22 billion
  • Shares in PharmAust closed grey this afternoon at 10 cents each
Previous article
BasisBank: Partners with Backbase to deliver hyper personalized experiences
Next article
SIA: Preliminary consolidated financial results at 31 December 2020 approved
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Coastal Bank Partners with Tempo to Strengthen Cross-Border Money Transfers

The partnership aims to enhance international money movement solutions.Highlights: Coastal Bank has partnered with Tempo for improved cross-border...
FinTech

Lloyds Accelerates Homebuying with Fully Digital Service

New platform aims to reduce waiting times for mortgage approvals.Highlights: Lloyds introduces a fully digital homebuying service.Service aims...
Blogs

AI in Fintech: Revolutionizing the Financial Industry

AI in fintech is changing how financial services operate. It's more than just a buzzword; it's a powerful...
Blogs

Revolut $200B Valuation: What It Means for Fintech Investors

The Revolut $200B valuation has captured the attention of fintech investors worldwide. This massive figure highlights Revolut's explosive...